Integrin beta 6

This article was updated by an external expert under a dual publication model. The corresponding peer-reviewed article was published in the journal Gene: X. Click to view.
From Wikipedia, the free encyclopedia
(Redirected from ITGB6 (gene))
ITGB6
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesITGB6, AI1H, Integrin, beta 6, integrin subunit beta 6
External IDsOMIM: 147558 MGI: 96615 HomoloGene: 685 GeneCards: ITGB6
Orthologs
SpeciesHumanMouse
Entrez

3694

16420

Ensembl

ENSG00000115221

ENSMUSG00000026971

UniProt

P18564

Q9Z0T9

RefSeq (mRNA)

NM_001159564
NM_021359

RefSeq (protein)

NP_001153036
NP_067334

Location (UCSC)Chr 2: 160.1 – 160.2 MbChr 2: 60.43 – 60.55 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Integrin beta-6 is a protein that in humans is encoded by the ITGB6 gene.[5][6][7] It is the β6 subunit of the integrin αvβ6. Integrins are αβ heterodimeric glycoproteins which span the cell’s membrane, integrating the outside and inside of the cell. Integrins bind to specific extracellular proteins in the extracellular matrix or on other cells and subsequently transduce signals intracellularly to affect cell behaviour. One α and one β subunit associate non-covalently to form 24 unique integrins found in mammals.[8] While some β integrin subunits partner with multiple α subunits, β6 associates exclusively with the αv subunit. Thus, the function of ITGB6 is entirely associated with the integrin αvβ6.

Discovery[edit]

The β6 subunit and ITGB6 sequence was discovered by Professor Dean Sheppard and colleagues at the University of California, San Francisco in the early 1990s in guinea pig cells.[9] Further investigation by research groups from the University of Madrid and University of Auckland found that ITGB6 was located on chromosome 2q at position 24.2.[10]

In the past decade, significant research has been performed toward identifying the location of regions within the ITGB6 gene which both promote and suppress ITGB6 expression. Of note, binding regions for transcription factors STAT3 and C/EBPα were found, and basic normal cell expression of ITGB6 is thought to be regulated primarily by these proteins.[11][12] Other transcription factors such as Ets-1 and Smad3 have also been shown to increase ITGB6 expression,[13] while Elk1 binding is able to decrease expression.[14] It is also known that ITGB6 expression is regulated epigenetically via histone acetylation.[15]

It is also known that αvβ6 expression is regulated post-transcriptionally. ITGB6 mRNA is characteristically ‘weak’, meaning it is less likely to be translated than ‘strong’ mRNA. eIF4E is a protein which binds to ‘weak’ mRNA to upregulate translation of the protein.[16] Disruption of eIF4E expression results in a significantly reduced expression of ITGB6.[17]

Mouse models[edit]

The first ITGB6-knockout mouse model was developed in 1996.[18] The mice grew normally, with no difference in wound healing ability. However, there was a significant amount of inflammation in the skin and lungs. This was the observation eventually leading to the discovery that αvβ6 activates TGF-β1,[19] as the mice had a similar phenotype to TGF-β1 deficient mice. The mice also developed temporary baldness, possibly due to the role αvβ6 plays in hair follicle regeneration.

While both TGF-β-/- and itgb6-/- mice have many similar characteristics, TGF-β1 deficient mice suffer from poorer health and symptoms not observed in itgb6-/- mice. This is because TGF-β1 can still be activated by other proteins such as Thrombospondin-1. In itgb6/thrombospondin 1 (tsp-1) double-null mice, there is a higher incidence of inflammation more consistent with the TGF-β1 null mice phenotype.[20] Additionally, this study observed that the itgb6-/- mice developed many more benign and malignant tumours compared to both the wild type and tsp-1-/- mice.

Studies with longer term follow up of itgb6-/- mice observed an eventual development of emphysema.[21] Matrix metallopeptidase 12 (MMP12) is an enzyme strongly associated with the development of emphysema, and was expressed 200-fold higher compared to the normal mice in alveolar macrophages. The mice also had abnormally large alveoli which worsened as the mice aged.

Another consistent observation in itgb6-/- mice is periodontitis.[22] αvβ6 is expressed in the junctional epithelium of the gums, and is involved in the adhesion of the gingiva to the teeth. Incomplete adhesion of the gums to the teeth can cause ‘pockets’ to form which are prone to infection, resulting in chronic periodontal disease.[23] Some mice also develop amelogenesis imperfecta, a disorder causing the teeth to develop abnormally.[24]

Function[edit]

Integrin αvβ6 is found exclusively on epithelial cells.[25] In most resting normal cells, little ITGB6 is produced, however the highest levels are found in the stomach, gall bladder and lung. ITGB6 levels increase in cells remodelling tissues so αvβ6 expression is increased in development,[25] wound healing,[26][27] but also in fibrosis[19] and cancer.[28]

The principal function of αvβ6 is the activation of cytokine transforming growth factor-b1 (TGF-β1).[19][29] Latent-TGF-β1 is bound to the extracellular matrix, covered by its pro-peptide latency associated peptide (LAP).[29] αvβ6 binds LAP, and through cytoskeletal force releases TGF-β1.[30] TGF-β1 regulates multiple processes including cell proliferation,[31][32] differentiation,[32] angiogenesis,[33] epithelial-mesenchymal-transition (EMT)[34] and immune suppression.[35] These processes combine to heal wounds but when uncontrolled can promote tissue pathologies.

Clinical significance[edit]

While αvβ6 promotes normal functions such as wound repair, excess αvβ6 production promotes diseases such fibrosis and cancer. High αvβ6 expression in fibrosis and cancer is usually associated with a poorer prognosis.

Fibrosis[edit]

Fibrosis occurs in response to chronic tissue insult and results in the deposit of excess collagen by activated fibroblasts in the matrix resulting in hardening of tissue. Fibroblasts are mesenchymal cells in all tissues that maintain the normal tissue matrix. When they become activated, as occurs in wound healing, they secrete extra matrix proteins and cytokines to promote wound repair.[36] Chronic activation of fibroblasts can result in diseases such as pulmonary fibrosis,[37] where the hardening and thickening of the lung tissue makes it difficult for patients to breathe.

A major driver of fibroblast activation is TGF-β[38] and as αvβ6 expression is increased in response to tissue damage,[26] and is a principal activator of TGF-β, it is therefore a potential drug target in treating fibrosis. αvβ6 can promote fibrosis in kidney, lung and skin, despite αvβ6 being almost absent in their healthy equivalents.

Cancer[edit]

Increased αvβ6 expression occurs in up to one third of solid tumours including breast cancer, lung cancer and pancreatic cancer. Because it is not found on most normal cells, it is a potential therapeutic and imaging target in cancer research. When αvβ6 is over-expressed in cancers it often correlates with poorer overall survival.

Integrin αvβ6 promotes tumour progression in multiple ways. Through its cytoplasmic tail it promotes cancer cell migration,[39] increased secretion of matrix metalloproteinases (MMPs) that can degrade the ECM,[40] leading to increased invasion. Intracellular signals generated by αvβ6 increase pErk and pAkt that increase cell proliferation and survival, respectively.[41] Through its extracellular domain it activates TGF-β1 which increases processes that aid cancer progression including angiogenesis,[33] activation of fibroblasts (now called Cancer Associated Fibroblasts),[42] immune suppression.[35] and epithelial-to-mesenchymal transition (EMT)[34] EMT is the process by which epithelial cells adopt a mesenchymal phenotype, breaking away from neighbouring epithelial cells and becoming more migratory, a crucial stage in the development of cancer.[43] In cancer, this promotes invasion of the local healthy tissue and ultimately spread to other parts of the body. αvβ6 can be found in cells which are undergoing EMT.[44][45]

ITGB6 deficiency[edit]

Recorded cases of people who are ITGB6 deficient are rare. The first reported case was in 2013 following whole genome sequencing of a 7-year-old girl with amelogenesis imperfecta,[46] a disease affecting the development of teeth. While multiple patients with amelogenesis imperfecta have since been found to have ITGB6 mutations,[47][48] there were no other clinical symptoms reported in the majority of these cases.

In 2016 a family in Pakistan were found to have dysfunctional ITGB6 resulting in alopecia, intellectual disabilities and symptoms consistent with amelogenesis imperfecta.[48] The clinical phenotype of these cases does not fully reflect the phenotype observed in mouse models, and of note, there was no reference to any chronic inflammation or emphysema.

Interactions[edit]

Integrin beta 6 has been shown to interact with FHL2.[49]

Notes[edit]

References[edit]

  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000115221 – Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000026971 – Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ Krissansen GW, Yuan Q, Jenkins D, Jiang WM, Rooke L, Spurr NK, et al. (February 1992). "Chromosomal locations of the genes coding for the integrin beta 6 and beta 7 subunits". Immunogenetics. 35 (1): 58–61. doi:10.1007/bf00216629. PMID 1729173. S2CID 13363937.
  6. ^ Weinacker A, Chen A, Agrez M, Cone RI, Nishimura S, Wayner E, et al. (March 1994). "Role of the integrin alpha v beta 6 in cell attachment to fibronectin. Heterologous expression of intact and secreted forms of the receptor". The Journal of Biological Chemistry. 269 (9): 6940–8. doi:10.1016/S0021-9258(17)37465-3. PMID 8120056.
  7. ^ "Entrez Gene: ITGB6 integrin, beta 6".
  8. ^ Hynes RO (September 2002). "Integrins: bidirectional, allosteric signaling machines". Cell. 110 (6): 673–87. doi:10.1016/s0092-8674(02)00971-6. PMID 12297042. S2CID 30326350.
  9. ^ Sheppard D, Rozzo C, Starr L, Quaranta V, Erle DJ, Pytela R (July 1990). "Complete amino acid sequence of a novel integrin beta subunit (beta 6) identified in epithelial cells using the polymerase chain reaction". The Journal of Biological Chemistry. 265 (20): 11502–7. doi:10.1016/S0021-9258(19)38425-X. PMID 2365683.
  10. ^ Krissansen GW, Yuan Q, Jenkins D, Jiang WM, Rooke L, Spurr NK, et al. (1992). "Chromosomal locations of the genes coding for the integrin beta 6 and beta 7 subunits". Immunogenetics. 35 (1): 58–61. doi:10.1007/bf00216629. PMID 1729173. S2CID 13363937.
  11. ^ Xu M, Chen X, Yin H, Yin L, Liu F, Fu Y, et al. (2015). "Cloning and characterization of the human integrin β6 gene promoter". PLOS ONE. 10 (3): e0121439. Bibcode:2015PLoSO..1021439X. doi:10.1371/journal.pone.0121439. PMC 4376883. PMID 25816241.
  12. ^ Azare J, Leslie K, Al-Ahmadie H, Gerald W, Weinreb PH, Violette SM, Bromberg J (June 2007). "Constitutively activated Stat3 induces tumorigenesis and enhances cell motility of prostate epithelial cells through integrin beta 6". Molecular and Cellular Biology. 27 (12): 4444–53. doi:10.1128/MCB.02404-06. PMC 1900039. PMID 17438134.
  13. ^ Bates RC, Bellovin DI, Brown C, Maynard E, Wu B, Kawakatsu H, et al. (February 2005). "Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma". The Journal of Clinical Investigation. 115 (2): 339–47. doi:10.1172/JCI23183. PMC 544606. PMID 15668738.
  14. ^ Tatler AL, Habgood A, Porte J, John AE, Stavrou A, Hodge E, et al. (April 2016). "Reduced Ets Domain-containing Protein Elk1 Promotes Pulmonary Fibrosis via Increased Integrin αvβ6 Expression". The Journal of Biological Chemistry. 291 (18): 9540–53. doi:10.1074/jbc.M115.692368. PMC 4850293. PMID 26861876.
  15. ^ Xu M, Yin L, Cai Y, Hu Q, Huang J, Ji Q, et al. (May 2018). "Epigenetic regulation of integrin β6 transcription induced by TGF-β1 in human oral squamous cell carcinoma cells". Journal of Cellular Biochemistry. 119 (5): 4193–4204. doi:10.1002/jcb.26642. PMID 29274289. S2CID 4330899.
  16. ^ Graff JR, Zimmer SG (2003). "Translational control and metastatic progression: enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs". Clinical & Experimental Metastasis. 20 (3): 265–73. doi:10.1023/A:1022943419011. PMID 12741684. S2CID 21561578.
  17. ^ Enyu L, Zhengchuan N, Jiayong W, Benjia L, Qi S, Ruixi Q, et al. (August 2015). "Integrin β6 can be translationally regulated by eukaryotic initiation factor 4E: Contributing to colonic tumor malignancy". Tumour Biology. 36 (8): 6541–50. doi:10.1007/s13277-015-3348-8. PMID 25982998. S2CID 2656185.
  18. ^ Huang XZ, Wu JF, Cass D, Erle DJ, Corry D, Young SG, et al. (May 1996). "Inactivation of the integrin beta 6 subunit gene reveals a role of epithelial integrins in regulating inflammation in the lung and skin". The Journal of Cell Biology. 133 (4): 921–8. doi:10.1083/jcb.133.4.921. PMC 2120829. PMID 8666675.
  19. ^ a b c Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu J, et al. (February 1999). "The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis". Cell. 96 (3): 319–28. doi:10.1016/s0092-8674(00)80545-0. PMID 10025398.
  20. ^ Ludlow A, Yee KO, Lipman R, Bronson R, Weinreb P, Huang X, et al. (April 2005). "Characterization of integrin beta6 and thrombospondin-1 double-null mice". Journal of Cellular and Molecular Medicine. 9 (2): 421–37. doi:10.1111/j.1582-4934.2005.tb00367.x. PMC 6740207. PMID 15963261.
  21. ^ Morris DG, Huang X, Kaminski N, Wang Y, Shapiro SD, Dolganov G, et al. (March 2003). "Loss of integrin alpha(v)beta6-mediated TGF-beta activation causes Mmp12-dependent emphysema". Nature. 422 (6928): 169–73. Bibcode:2003Natur.422..169M. doi:10.1038/nature01413. PMID 12634787. S2CID 4407206.
  22. ^ Ghannad F, Nica D, Fulle MI, Grenier D, Putnins EE, Johnston S, et al. (May 2008). "Absence of alphavbeta6 integrin is linked to initiation and progression of periodontal disease". The American Journal of Pathology. 172 (5): 1271–86. doi:10.2353/ajpath.2008.071068. PMC 2329836. PMID 18385522.
  23. ^ Bi J, Koivisto L, Pang A, Li M, Jiang G, Aurora S, et al. (June 2017). "Suppression of αvβ6 Integrin Expression by Polymicrobial Oral Biofilms in Gingival Epithelial Cells". Scientific Reports. 7 (1): 4411. Bibcode:2017NatSR...7.4411B. doi:10.1038/s41598-017-03619-7. PMC 5493688. PMID 28667248.
  24. ^ Mohazab L, Koivisto L, Jiang G, Kytömäki L, Haapasalo M, Owen GR, et al. (February 2013). "Critical role for αvβ6 integrin in enamel biomineralization". Journal of Cell Science. 126 (Pt 3): 732–44. doi:10.1242/jcs.112599. PMID 23264742.
  25. ^ a b Breuss JM, Gallo J, DeLisser HM, Klimanskaya IV, Folkesson HG, Pittet JF, et al. (June 1995). "Expression of the beta 6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling". Journal of Cell Science. 108 ( Pt 6) (6): 2241–51. doi:10.1242/jcs.108.6.2241. PMID 7673344.
  26. ^ a b Haapasalmi K, Zhang K, Tonnesen M, Olerud J, Sheppard D, Salo T, et al. (January 1996). "Keratinocytes in human wounds express alpha v beta 6 integrin". The Journal of Investigative Dermatology. 106 (1): 42–8. doi:10.1111/1523-1747.ep12327199. PMID 8592080.
  27. ^ Eslami A, Gallant-Behm CL, Hart DA, Wiebe C, Honardoust D, Gardner H, et al. (June 2009). "Expression of integrin alphavbeta6 and TGF-beta in scarless vs scar-forming wound healing". The Journal of Histochemistry and Cytochemistry. 57 (6): 543–57. doi:10.1369/jhc.2009.952572. PMC 2690407. PMID 19223298.
  28. ^ Bandyopadhyay A, Raghavan S (July 2009). "Defining the role of integrin alphavbeta6 in cancer". Current Drug Targets. 10 (7): 645–52. doi:10.2174/138945009788680374. PMC 2888263. PMID 19601768.
  29. ^ a b Annes JP, Chen Y, Munger JS, Rifkin DB (June 2004). "Integrin alphaVbeta6-mediated activation of latent TGF-beta requires the latent TGF-beta binding protein-1". The Journal of Cell Biology. 165 (5): 723–34. doi:10.1083/jcb.200312172. PMC 2172370. PMID 15184403.
  30. ^ Shi M, Zhu J, Wang R, Chen X, Mi L, Walz T, Springer TA (June 2011). "Latent TGF-β structure and activation". Nature. 474 (7351): 343–9. doi:10.1038/nature10152. PMC 4717672. PMID 21677751.
  31. ^ Syed V (June 2016). "TGF-β Signaling in Cancer". Journal of Cellular Biochemistry. 117 (6): 1279–87. doi:10.1002/jcb.25496. PMID 26774024. S2CID 18884315.
  32. ^ a b Massagué J (October 2012). "TGFβ signalling in context". Nature Reviews. Molecular Cell Biology. 13 (10): 616–30. doi:10.1038/nrm3434. PMC 4027049. PMID 22992590.
  33. ^ a b Ferrari G, Cook BD, Terushkin V, Pintucci G, Mignatti P (May 2009). "Transforming growth factor-beta 1 (TGF-beta1) induces angiogenesis through vascular endothelial growth factor (VEGF)-mediated apoptosis". Journal of Cellular Physiology. 219 (2): 449–58. doi:10.1002/jcp.21706. PMC 2749291. PMID 19180561.
  34. ^ a b Xu J, Lamouille S, Derynck R (February 2009). "TGF-beta-induced epithelial to mesenchymal transition". Cell Research. 19 (2): 156–72. doi:10.1038/cr.2009.5. PMC 4720263. PMID 19153598.
  35. ^ a b Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA (2006). "Transforming growth factor-beta regulation of immune responses". Annual Review of Immunology. 24: 99–146. doi:10.1146/annurev.immunol.24.021605.090737. PMID 16551245.
  36. ^ Barrientos S, Stojadinovic O, Golinko MS, Brem H, Tomic-Canic M (September 2008). "Growth factors and cytokines in wound healing". Wound Repair and Regeneration. 16 (5): 585–601. doi:10.1111/j.1524-475X.2008.00410.x. PMID 19128254. S2CID 12369824.
  37. ^ King TE, Pardo A, Selman M (December 2011). "Idiopathic pulmonary fibrosis". Lancet. 378 (9807): 1949–61. doi:10.1016/S0140-6736(11)60052-4. PMID 21719092. S2CID 6658229.
  38. ^ Chen H, Yang WW, Wen QT, Xu L, Chen M (December 2009). "TGF-beta induces fibroblast activation protein expression; fibroblast activation protein expression increases the proliferation, adhesion, and migration of HO-8910PM [corrected]". Experimental and Molecular Pathology. 87 (3): 189–94. doi:10.1016/j.yexmp.2009.09.001. PMID 19747910.
  39. ^ Coughlan L, Vallath S, Saha A, Flak M, McNeish IA, Vassaux G, et al. (July 2009). "In vivo retargeting of adenovirus type 5 to alphavbeta6 integrin results in reduced hepatotoxicity and improved tumor uptake following systemic delivery". Journal of Virology. 83 (13): 6416–28. doi:10.1128/JVI.00445-09. PMC 2698540. PMID 19369326.
  40. ^ Morgan MR, Thomas GJ, Russell A, Hart IR, Marshall JF (June 2004). "The integrin cytoplasmic-tail motif EKQKVDLSTDC is sufficient to promote tumor cell invasion mediated by matrix metalloproteinase (MMP)-2 or MMP-9". The Journal of Biological Chemistry. 279 (25): 26533–9. doi:10.1074/jbc.M401736200. PMID 15067014.
  41. ^ Ahmed N, Niu J, Dorahy DJ, Gu X, Andrews S, Meldrum CJ, et al. (February 2002). "Direct integrin alphavbeta6-ERK binding: implications for tumour growth". Oncogene. 21 (9): 1370–80. doi:10.1038/sj.onc.1205286. PMID 11857080. S2CID 29988894.
  42. ^ Midgley AC, Rogers M, Hallett MB, Clayton A, Bowen T, Phillips AO, Steadman R (May 2013). "Transforming growth factor-β1 (TGF-β1)-stimulated fibroblast to myofibroblast differentiation is mediated by hyaluronan (HA)-facilitated epidermal growth factor receptor (EGFR) and CD44 co-localization in lipid rafts". The Journal of Biological Chemistry. 288 (21): 14824–38. doi:10.1074/jbc.M113.451336. PMC 3663506. PMID 23589287.
  43. ^ Kalluri R, Weinberg RA (June 2009). "The basics of epithelial-mesenchymal transition". The Journal of Clinical Investigation. 119 (6): 1420–8. doi:10.1172/JCI39104. PMC 2689101. PMID 19487818.
  44. ^ Ramos DM, Dang D, Sadler S (January 2009). "The role of the integrin alpha v beta6 in regulating the epithelial to mesenchymal transition in oral cancer". Anticancer Research. 29 (1): 125–30. PMID 19331141.
  45. ^ Bates RC, Mercurio AM (April 2005). "The epithelial-mesenchymal transition (EMT) and colorectal cancer progression". Cancer Biology & Therapy. 4 (4): 365–70. doi:10.4161/cbt.4.4.1655. PMID 15846061.
  46. ^ Wang SK, Choi M, Richardson AS, Reid BM, Lin BP, Wang SJ, et al. (April 2014). "ITGB6 loss-of-function mutations cause autosomal recessive amelogenesis imperfecta". Human Molecular Genetics. 23 (8): 2157–63. doi:10.1093/hmg/ddt611. PMC 3959820. PMID 24305999.
  47. ^ Poulter JA, Brookes SJ, Shore RC, Smith CE, Abi Farraj L, Kirkham J, et al. (April 2014). "A missense mutation in ITGB6 causes pitted hypomineralized amelogenesis imperfecta". Human Molecular Genetics. 23 (8): 2189–97. doi:10.1093/hmg/ddt616. PMC 3959822. PMID 24319098.
  48. ^ a b Ansar M, Jan A, Santos-Cortez RL, Wang X, Suliman M, Acharya A, et al. (August 2016). "Expansion of the spectrum of ITGB6-related disorders to adolescent alopecia, dentogingival abnormalities and intellectual disability". European Journal of Human Genetics. 24 (8): 1223–7. doi:10.1038/ejhg.2015.260. PMC 4970676. PMID 26695873.
  49. ^ Wixler V, Geerts D, Laplantine E, Westhoff D, Smyth N, Aumailley M, et al. (October 2000). "The LIM-only protein DRAL/FHL2 binds to the cytoplasmic domain of several alpha and beta integrin chains and is recruited to adhesion complexes". The Journal of Biological Chemistry. 275 (43): 33669–78. doi:10.1074/jbc.M002519200. PMID 10906324.

Further reading[edit]

External links[edit]

Retrieved from "https://en.wikipedia.org/w/index.php?title=Integrin_beta_6&oldid=1191453137"